Treatment ( Actinium Ac 225-DOTA-Daratumumab) for Myelodysplastic Syndrome

"As per the information provided on clinicaltrials.gov, recruitment for this particular study is presently closed. The trial was initially listed on 6/18/2024 and last modified on 2/23/2024. Although enrollment is not active at the moment, there are currently 2954 alternative studies available for patient participation."

"On a rating scale from 1 to 3, our team at Power assesses the safety of Treatment (Actinium Ac 225-DOTA-Daratumumab) as a level one. This judgment is informed by the fact that this trial is in its initial Phase, where data supporting both efficacy and safety are scarce."

"The primary aim of this medical investigation, which will be evaluated for a duration extending up to 24 months after transplantation, is to monitor the frequency of adverse events according to Bearman's criteria. Secondary objectives encompass assessing Overall Survival (OS), defined as the period from initiation of treatment per protocol until demise or last follow-up using Kaplan-Meier analysis; tracking Cumulative Incidence of Relapse/Progression (CIR) starting from therapy initiation, with non-relapse mortality taken into account as a competing risk; and scrutinizing Non-Relapse Mortality (NRM), calculated from commencement of therapy till death unrelated to disease or"